AIM ImmunoTech Files 8-K for Bylaw Amendments & Financials

Ticker: AIM · Form: 8-K · Filed: Aug 1, 2024 · CIK: 946644

Aim Immunotech INC. 8-K Filing Summary
FieldDetail
CompanyAim Immunotech INC. (AIM)
Form Type8-K
Filed DateAug 1, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, financials, filing

TL;DR

AIM ImmunoTech filed an 8-K on 7/31 for bylaw changes and financials.

AI Summary

AIM ImmunoTech Inc. filed an 8-K on July 31, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, formerly known as Hemispherx Biopharma Inc., is incorporated in Delaware and operates in the biological products sector.

Why It Matters

This filing indicates corporate governance updates and the release of financial information, which are crucial for investors to assess the company's operational and financial health.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure and does not contain information suggesting immediate or significant risk.

Key Players & Entities

FAQ

What specific amendments were made to AIM ImmunoTech's articles of incorporation or bylaws?

The filing indicates amendments were made, but the specific details of these amendments are not provided in the provided text.

What is the primary business of AIM ImmunoTech Inc.?

AIM ImmunoTech Inc. operates in the Biological Products sector, specifically excluding diagnostic substances.

When was AIM ImmunoTech Inc. formerly known as?

The company was formerly known as Hemispherx Biopharma Inc., with a name change date of June 14, 1995.

What is the principal executive office address for AIM ImmunoTech Inc.?

The principal executive offices are located at 2117 SW Highway 484, Ocala, FL 34473.

What is the SEC file number for AIM ImmunoTech Inc.?

The SEC file number for AIM ImmunoTech Inc. is 001-27072.

Filing Stats: 618 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-08-01 06:05:15

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AIM ImmunoTech Inc. Date: July 31, 2024 By /s/ Thomas K. Equels Thomas K. Equels, CEO

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing